Lotus Pharmaceutical Co., Ltd.
Records under this name other than patents Lotus Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Lotus Pharmaceutical Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,088,818 | Catechol-Based Derivatives for Treating or Preventing Diabetics Formerly held Term ended Term ended Sep 3, 2026 · Medium confidence | Term ended | Term ended Sep 3, 2026 | Medium confidence |
| US 7,045,516 | Benzoxazole Derivatives and Medicaments Comprising Said Derivatives as Active Ingredient Lapsed on the fee record Ended May 16, 2018 · High confidence | Lapsed on the fee record | Ended May 16, 2018 | High confidence |
| US 7,655,255 | Topical composition for transdermal administration Formerly held Lapsed on the fee record Ended Feb 2, 2018 · USPTO record | Lapsed on the fee record | Ended Feb 2, 2018 | USPTO record |
| US 6,037,342 | Serotonin 5-HT.sub.3 receptor partial activator Term ended Term ended May 6, 2017 · USPTO record | Term ended | Term ended May 6, 2017 | USPTO record |
| US 6,867,226 | Serotonin 5-HT3 receptor partial activator Lapsed on the fee record Ended Mar 15, 2017 · USPTO record | Lapsed on the fee record | Ended Mar 15, 2017 | USPTO record |
| US 6,552,057 | Serotonin 5-HT3 receptor partial activator Lapsed on the fee record Ended Apr 22, 2015 · USPTO record | Lapsed on the fee record | Ended Apr 22, 2015 | USPTO record |
| US 7,057,044 | Aporphine and oxoaporphine compounds and pharmaceutical use thereof Lapsed on the fee record Ended Jun 6, 2014 · USPTO record | Lapsed on the fee record | Ended Jun 6, 2014 | USPTO record |
| US 6,333,328 | Serotonin 5-HT3 receptor partial activator Lapsed on the fee record Ended Dec 25, 2013 · USPTO record | Lapsed on the fee record | Ended Dec 25, 2013 | USPTO record |
| US 6,297,246 | Serotonin 5-HT3, receptor partial activator Lapsed on the fee record Ended Oct 2, 2013 · USPTO record | Lapsed on the fee record | Ended Oct 2, 2013 | USPTO record |
| US 7,294,715 | Aporphine and oxoaporphine compounds and pharmaceutical use thereof Lapsed on the fee record Ended Nov 13, 2011 · USPTO record | Lapsed on the fee record | Ended Nov 13, 2011 | USPTO record |